[Allogeneic bone marrow transplantation after the treatment of alpha-IFN and high-dose SNMC in two cases of acute myeloblastic leukemia with post-transfusional non-A, non-B hepatitis].
Two patients of acute myeloblastic leukemia (M2) with post-transfusional hepatitis (non-A, non-B) were treated with alpha-IFN and high-dose SNMC before allogeneic bone marrow transplantation. Bone marrow transplantation from HLA identical and MLR negative sibling donor was carried out when their hepatic functions were almost normalized. In the early phase after bone marrow transplantation, the hepatic function in both two cases has been stable, thus indicating that this treatment should be tried for reducing hepatic dysfunction and for safety bone marrow transplantation.
Hashino
S
S
Imamura
M
M
Kobayashi
H
H
Tanaka
M
M
Fukuhara
T
T
Fujimoto
H
H
Karino
Y
Y
Yoshida
J
J
Sakurada
K
K
Matsushima
T
T
D000328:Adult; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005998:Glycine / Q000008:administration & dosage; D006034:Glycyrrhetinic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D006526:Hepatitis C / Q000628:therapy* / Q000635:transmission; D006525:Hepatitis, Viral, Human / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000601:surgery*; D008297:Male; D065227:Transfusion Reaction
D007370:Interferon Type I; D006034:Glycyrrhetinic Acid; D005998:Glycine